Aimovig, Emgality, Ajovy, and Vyepti: Injectable CGRP Medications for Post-Traumatic Migraine

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | August 8, 2024 | 9 min read

Injectable CGRP monoclonal antibodies — Aimovig, Emgality, Ajovy, and Vyepti — represent the gold standard of preventive migraine therapy. Administered monthly or quarterly, they are increasingly prescribed for personal injury patients who develop post-traumatic migraine after accidents and require sustained neurological protection.

Aimovig, Emgality, Ajovy, and Vyepti: Injectable CGRP Medications for Post-Traumatic Migraine

When oral gepants are insufficient for managing post-traumatic migraine, or when a neurologist determines that a patient requires longer-acting preventive coverage, the injectable CGRP monoclonal antibodies become the next clinical step. These are large-protein biologics — administered by injection or IV infusion — that provide extended CGRP pathway blockade lasting weeks to months from a single administration.

Four injectable CGRP medications are currently FDA-approved for migraine prevention. Each works through the same general mechanism but differs in administration frequency, injection method, and specific molecular target. For personal injury attorneys and patients, understanding these drugs and what their prescription means is increasingly important as they become more widely prescribed in the post-accident neurological care setting.

[!KEY] Injectable CGRP monoclonal antibodies — Aimovig, Emgality, Ajovy, and Vyepti — represent the highest tier of post-traumatic migraine prevention, generating monthly or quarterly specialist records that powerfully document ongoing neurological injury management.

[!SOURCE] FDA CGRP Drug Approvals — FDA-approved CGRP antagonists for migraine prevention and treatment.

How CGRP Monoclonal Antibodies Work

Unlike gepants (which are small oral molecules that block the CGRP receptor in real time), monoclonal antibodies are large protein molecules that bind to either the CGRP ligand itself or its receptor and neutralize it over an extended period. Because they are large proteins, they cannot cross the blood-brain barrier — they act peripherally, blocking CGRP in the meninges and trigeminal system.

This peripheral mechanism is clinically significant. CGRP monoclonal antibodies do not cause the central nervous system side effects (cognitive impairment, fatigue, depression) associated with older migraine preventives like topiramate or valproate. For personal injury patients who need to maintain cognitive function for work, legal proceedings, and rehabilitation, this side effect profile is meaningfully better.

The extended duration of action — weeks to months from a single injection — is achieved because large proteins are cleared from the body slowly, maintaining therapeutic drug levels between administrations.

The Four Injectable CGRP Medications

Aimovig (Erenumab)

Erenumab was the first CGRP monoclonal antibody approved by the FDA, in May 2018. Unlike the other three, it targets the CGRP receptor rather than the CGRP ligand itself — a distinction with some clinical implications for patients who fail one drug and try another.

Administration: Monthly subcutaneous injection (70mg or 140mg). Patients self-administer using an autoinjector pen, similar to an EpiPen. The injection takes seconds.

FDA indication: Prevention of migraine in adults.

Clinical evidence: In the STRIVE trial, erenumab reduced monthly migraine days by approximately 3.2 (70mg) and 3.7 (140mg) compared to 1.8 for placebo in patients with episodic migraine averaging 8 days per month. For episodic migraine prevention, this represents a clinically meaningful improvement.

For PI patients: Aimovig's monthly self-injection schedule creates a clear monthly documentation point. Each autoinjector dispensed by the pharmacy generates a record of ongoing preventive migraine treatment.

Emgality (Galcanezumab)

Galcanezumab received FDA approval in September 2018 and targets the CGRP ligand rather than its receptor. It also has the distinction of being the only CGRP monoclonal antibody with FDA approval for cluster headache prevention — a condition that can be triggered or worsened by head trauma.

Administration: Monthly subcutaneous injection (120mg). A 240mg loading dose (two 120mg injections) is administered in the first month.

FDA indications: Prevention of episodic migraine, prevention of chronic migraine, and prevention of episodic cluster headache.

Clinical evidence: The EVOLVE trials demonstrated reduction of monthly migraine days by approximately 4.7 days compared to 2.8 for placebo in episodic migraine patients. In chronic migraine, the REGAIN trial showed meaningful reductions in headache frequency.

For PI patients: The loading dose in the first month — two injections rather than one — creates a particularly strong documentation record at treatment initiation, signaling the treating neurologist's assessment that aggressive upfront CGRP blockade was warranted.

Ajovy (Fremanezumab)

Fremanezumab received FDA approval in September 2018 and offers a distinctive feature that is particularly relevant for personal injury cases: it can be administered either monthly or quarterly.

Administration: Either 225mg monthly subcutaneous injection OR 675mg every three months (quarterly). The quarterly option is three 225mg injections administered at once.

FDA indication: Prevention of migraine in adults (both episodic and chronic).

Clinical evidence: The HALO trials demonstrated fremanezumab's efficacy for both episodic and chronic migraine prevention, with meaningful reductions in monthly migraine days for both the monthly and quarterly dosing schedules.

For PI patients: The quarterly dosing option is strategically notable for lien documentation purposes. A single quarterly injection establishes a 90-day treatment record from a single pharmacy dispensing event. A patient treated with quarterly Ajovy for one year receives four injections — four distinct, high-value pharmacy records documenting continuous neurological management.

Vyepti (Eptinezumab)

Eptinezumab is the newest and most clinically distinctive of the four injectable CGRP antibodies. Rather than subcutaneous self-injection, it is administered as an intravenous infusion in a clinical setting — every three months.

Administration: IV infusion of 100mg or 300mg over 30 minutes, every three months. Administered at an infusion center or neurology office.

FDA indication: Prevention of migraine in adults (both episodic and chronic).

Clinical evidence: The PROMISE trials showed that 300mg eptinezumab achieved pain freedom on day 1 of the first migraine after treatment in 26% of patients versus 15% for placebo — suggesting a particularly rapid onset compared to the subcutaneous options, which may require 2-3 months for full effect.

For PI patients: Vyepti's infusion administration creates the richest documentation — infusion center records in addition to pharmacy records, with prescriber documentation of the infusion visit. The 300mg dose is associated with the most robust efficacy in chronic migraine and represents the highest per-administration cost in the CGRP antibody class.

Comparing the Four Options

Which PI Patients Receive Injectable CGRP Antibodies?

Neurologists typically consider injectable CGRP antibodies for PI patients who:

• Have tried and not adequately responded to gepants (Qulipta, Nurtec ODT)
• Have chronic migraine (15+ headache days per month) requiring more robust prevention
• Have contraindications or intolerances to older preventive options
• Prefer monthly or quarterly administration over daily oral therapy
• Are being treated for cluster headache (Emgality specifically)

The choice between the four agents is guided by individual patient factors, prescriber preference, and sometimes insurance/lien formulary considerations.

[!KEY] When a neurologist prescribes an injectable CGRP antibody rather than defaulting to older preventives like topiramate, that clinical choice documents that the patient's post-traumatic migraine severity is at the top tier requiring biologic-class intervention — an argument that is very difficult for defense to dismiss with a bare IME assertion.

What Attorneys Should Know

Injectable = Specialist Documentation

Injectable CGRP antibodies are prescribed and managed by neurologists and headache specialists. The prescribing of these drugs is accompanied by a neurological evaluation, a diagnosis of migraine or cluster headache, and ongoing specialist follow-up — all of which generate specialist records that supplement the pharmacy lien documentation.

Monthly or Quarterly Records

Each injection generates a pharmacy dispensing record for subcutaneous options (Aimovig, Emgality, Ajovy) or an infusion center record plus pharmacy record for Vyepti. Over a standard treatment period of 6-12 months, this creates 6-12 monthly records or 2-4 quarterly records — each representing an ongoing clinical determination that preventive therapy is necessary.

No Generic Alternatives

All four injectable CGRP antibodies are biologic medications under patent protection. Biosimilars have not yet been approved for this class in the United States. The brand-name status is not elective — these are the only options in their class.

Strong Defense Against Minimization

Defense counsel frequently argue that post-accident headaches are benign and self-limiting. A client who has received quarterly Vyepti infusions or monthly Aimovig injections for 12 months has 12 months of documented specialist-prescribed, biologic-class neurological treatment. This is among the strongest possible pharmacological evidence that the post-traumatic migraine condition is genuine, diagnosed, and disabling.

[!KEY] All four injectable CGRP antibodies are branded biologics with no approved biosimilars — an adjuster's argument that pricing should be reduced to a "generic equivalent" fails because no generic equivalent exists; the prescribing choice is clinically binary, not a brand vs. generic decision.

Conclusion

The injectable CGRP monoclonal antibodies represent the most advanced pharmacological tools available for post-traumatic migraine prevention. For personal injury patients with significant migraine burden following an accident, they offer sustained neurological protection that older medications cannot match. For attorneys, they generate detailed, specialist-level documentation of ongoing neurological injury management that is highly defensible.

For lien-based coverage of injectable CGRP medications, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• CGRP Medications: A Complete Guide for Personal Injury
• Qulipta (Atogepant): Preventive Migraine Treatment After a Personal Injury
• Nurtec ODT (Rimegepant): Dual Acute and Preventive Migraine Treatment
• Why PI Patients Often Need Multiple Medications
• Pharmacy Services for Personal Injury Clients: How It Works
• What Are Medication Liens?